- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BA-679-BR | Spiriva®
tiotropium is an approved drug (FDA (2004))
Compound class: Synthetic organic
Comment: We have chosen to display the structure of the parent compound, tiotropium, as this reflects the compound used in the experimental data listed under the 'biological activity' tab, and the links in the table above also represent the parent compound. However, the INN-assigned compound is in complex with bromide, the approved drug is also administered in this preparation. Note that the activity data in PubChem for this compound is split between the parent and the preparation with bromide.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: tiotropium
|No information available.
|Summary of Clinical Use
|A bronchodilator used in the treatment of chronic obstructuve pulmonary disease (COPD).
In May 2015 the US FDA approved a fixed-dose combination of tiotropium bromide and olodaterol (Stiolto Respimat®) as 'a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema' Drugs.com. Later in 2015, the FDA expanded approval to include tiotropium's use as a single agent (Spiriva Respimat®) as maintenance treatment of asthma in adults and adolescents.
|Mechanism Of Action and Pharmacodynamic Effects
|Antagonist of muscarinic acetylcholine receptors. The antagonism of M3 receptors in the lungs causes relaxation of pulmonary smooth muscle resulting in a broncodilatory effect.
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)